GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Cyclically Adjusted Book per Share

Galectin Therapeutics (FRA:PHPN) Cyclically Adjusted Book per Share : €0.24 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Galectin Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was €-0.926. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.24 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Galectin Therapeutics's average Cyclically Adjusted Book Growth Rate was -20.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -6.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 20.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 21.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Galectin Therapeutics was 115.40% per year. The lowest was -70.50% per year. And the median was 4.35% per year.

As of today (2024-05-16), Galectin Therapeutics's current stock price is €2.60. Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €0.24. Galectin Therapeutics's Cyclically Adjusted PB Ratio of today is 10.83.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Galectin Therapeutics was 15.06. The lowest was 0.00. And the median was 0.00.


Galectin Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Galectin Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Cyclically Adjusted Book per Share Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.28 0.36 0.33 0.24

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.31 0.29 0.28 0.24

Competitive Comparison of Galectin Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.



Galectin Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.926/129.4194*129.4194
=-0.926

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.914 99.695 1.187
201406 0.840 100.560 1.081
201409 0.794 100.428 1.023
201412 0.751 99.070 0.981
201503 0.829 99.621 1.077
201506 0.648 100.684 0.833
201509 0.457 100.392 0.589
201512 0.557 99.792 0.722
201603 0.369 100.470 0.475
201606 0.211 101.688 0.269
201609 0.112 101.861 0.142
201612 0.088 101.863 0.112
201703 0.018 102.862 0.023
201706 -0.080 103.349 -0.100
201709 -0.148 104.136 -0.184
201712 -0.183 104.011 -0.228
201803 -0.136 105.290 -0.167
201806 0.017 106.317 0.021
201809 0.000 106.507 0.000
201812 -0.044 105.998 -0.054
201903 0.089 107.251 0.107
201906 0.772 108.070 0.925
201909 0.757 108.329 0.904
201912 0.686 108.420 0.819
202003 0.643 108.902 0.764
202006 0.541 108.767 0.644
202009 0.437 109.815 0.515
202012 0.316 109.897 0.372
202103 0.235 111.754 0.272
202106 0.208 114.631 0.235
202109 0.100 115.734 0.112
202112 0.005 117.630 0.006
202203 -0.129 121.301 -0.138
202206 -0.278 125.017 -0.288
202209 -0.418 125.227 -0.432
202212 -0.547 125.222 -0.565
202303 -0.704 127.348 -0.715
202306 -0.827 128.729 -0.831
202309 -0.805 129.860 -0.802
202312 -0.926 129.419 -0.926

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Galectin Therapeutics  (FRA:PHPN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galectin Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.60/0.24
=10.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Galectin Therapeutics was 15.06. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Galectin Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (FRA:PHPN) Business Description

Industry
Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines